Nevertheless, from a clinical perspective, the measurement of TP53 MB in uterine lavage appears as a promising tumor agnostic, minimally invasive molecular test for screening or risk stratification of ovarian cancer. This evidence concerns the gene TP53 and ovarian cancer.